The MOA is upstream and not so specific to AD pathology as the MABs. It's plausible that it could also treat other dementias which also are obv unmets needs. In practice, many cases of dementia are 'mixed' or blurred, so the inclusion of 'and dementia' might hint at a slightly broader label for Blarcamesine if approved. Do you think they just forgot to write 'and dementia' for Donnanemabs description?
Market Data 
Markets 
AI
